SAN FRANCISCO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the following upcoming investor conferences in August:
Go here to see the original:
89bio to Participate in Upcoming Investor Conferences
Related Post
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs - April 16th, 2024
- Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research... - April 16th, 2024
- Redemption Date Announced for Warrants - April 16th, 2024
- Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products - April 16th, 2024
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors - April 16th, 2024
- Publication Annual Report – Annual Shareholders' Meeting - April 16th, 2024
- Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American... - April 16th, 2024
- Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort - April 16th, 2024
- New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for... - April 16th, 2024
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million - April 16th, 2024
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC - April 16th, 2024
- Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders - April 16th, 2024
- GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents - April 16th, 2024
- TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation - April 16th, 2024
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - April 16th, 2024
- BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement - April 16th, 2024
- Faron Confirms Plans for the Coming Months Under New Leadership - April 16th, 2024
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 - April 16th, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease - April 16th, 2024
- Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 - April 16th, 2024
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024
- Nuvectis Pharma to Present at the 36th Annual Roth Conference - March 18th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - March 18th, 2024
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - March 18th, 2024
- Genmab Announces Initiation of Share Buy-Back Program - March 18th, 2024
- Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million - March 18th, 2024
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity - March 18th, 2024
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - March 18th, 2024
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement... - March 18th, 2024
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - March 18th, 2024
- Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - March 18th, 2024
- Sanofi: Information concerning the total number of voting rights and shares - February 2024 - March 18th, 2024
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - March 18th, 2024
- NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence - March 18th, 2024
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - March 18th, 2024
- Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - March 18th, 2024
- Financière de Tubize - Annual report 2023 - March 18th, 2024
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration - March 18th, 2024
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - March 18th, 2024
- Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - March 18th, 2024
- Pharvaris Announces Extraordinary Meeting of Shareholders - February 18th, 2024
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 18th, 2024
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right - February 18th, 2024
- Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 - February 18th, 2024
- Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent... - February 18th, 2024
- Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results - February 18th, 2024
- Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering - February 18th, 2024
- Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’... - February 18th, 2024
- Mdxhealth Announces Resignation of Board Member - February 18th, 2024
- Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020... - February 18th, 2024
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 - February 18th, 2024
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies - February 18th, 2024
- Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma - February 18th, 2024
- Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 - February 18th, 2024
- Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders - February 18th, 2024
- Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - February 18th, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - February 18th, 2024
- Soleno Therapeutics Strengthens Leadership Team with Key Appointments - January 25th, 2024
- CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a... - January 25th, 2024
- nmible partners with Velocity Clinical Research to streamline clinical trials patient stipends - January 25th, 2024
- Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets - January 25th, 2024
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment - January 25th, 2024
- Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products - January 25th, 2024
- AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced... - January 25th, 2024
- Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine... - January 25th, 2024
- OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors - January 25th, 2024
- PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing - January 25th, 2024
- Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards - January 25th, 2024
- CORRECTION -- Sirona Biochem Corporate Update January 2024 - January 25th, 2024
- 23andMe to Report FY2024 Third Quarter Financial Results - January 25th, 2024
- Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 25th, 2024
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux - January 25th, 2024
- AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device - January 25th, 2024
- Revive Therapeutics Ltd. Announces Offering of Up to $3 Million - January 25th, 2024
- BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress - January 25th, 2024
- Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population - January 25th, 2024
- Nicox Provides Fourth Quarter 2023 Financial and Business Highlights - January 25th, 2024
- Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance - December 22nd, 2023
- NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University - December 22nd, 2023
- Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive... - December 22nd, 2023